

SPECIALTY GUIDELINE MANAGEMENT

REBIF (interferon beta-1a)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Rebif is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Compendial Use

First clinical episode of multiple sclerosis with magnetic resonance imaging features consistent with multiple sclerosis

All other indications are considered experimental/investigational and are not covered benefits.

II. CRITERIA FOR INITIAL APPROVAL

A. Relapsing forms of multiple sclerosis

Authorization of 12 months may be granted to members who have been diagnosed with a relapsing form of multiple sclerosis (including relapsing-remitting and secondary progressive disease for those who continue to experience relapse).

B. Clinically isolated syndrome

Authorization of 12 months may be granted to members for the treatment of clinically isolated syndrome of multiple sclerosis.

III. CONTINUATION OF THERAPY

For all indications: Authorization of 12 months may be granted for members who are experiencing disease stability or improvement while receiving Rebif.

IV. OTHER CRITERIA

Members will not use Rebif concomitantly with other medications used for the treatment of multiple sclerosis, excluding Ampyra.

V. REFERENCES

1. Rebif [package insert]. Rockland, MA; EMD Serono Inc.; July 2019.

Reference number(s)
1839-A

2. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed April 19, 2019.
3. Clinical Pharmacology. [database online.] Tampa, FL: Gold Standard, Inc.; <http://www.clinicalpharmacology-ip.com/default.aspx> [available with subscription]. Accessed April 19, 2019.